Nutra Pharma Corp

nutrapharma.com

What Do They Do?

Sells over-the-counter pain relievers for consumers and animal owners, and develops drug candidates for neurological, autoimmune and viral diseases.

How Do They Make Money?

The company earns revenue from customer orders for its products, with sales counted when the products ship.

FY2025 revenue

Who Are Their Customers?

Consumers can buy products through company websites and online marketplaces; distributors market some products under their own brands, while Nyloxin is also sold in physician offices, clinics and small-chain pharmacies.

Customers above 10% of revenue, FY2025

of revenue from two customers (33%, 29%)

FY2024: 59% from two customers

Do Revenues Turn Into Profits?

No. It lost $2M in FY2025.

Operating income, FY2025

−568% of revenue

▲ +66% (Loss) vs FY2024 (−$878.4K, −357%)

Net income, FY2025

−795% of revenue

▲ +59% (Loss) vs FY2024 (−$1.3M, −522%)

Free cash flow, FY2025

−462% of revenue

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −59%; vs $84.5K in Q2 FY2025
Net income: ▼ Now a loss; vs $369.6K in Q2 FY2025

Sep 2, 2026 Pure Raw Supplies became the controlling stockholder Rik Deitsch transferred Series B preferred shares to Pure Raw Supplies as a gift, with no consideration paid.

Growing. Revenue grew 2.6x in 4 years, from $97.7K in FY2021 to $257.6K in FY2025, about 27% a year.

Who Do They Compete With?

Competes with Amgen, Sanofi-Aventis, Biogen-Idec, Cephalon, Genetech, Genzyme, Novartis, Regeneron, Roche, Bayer, Pentapharm, Knoll Pharmaceutical, Bristol-Myers Squibb, Medicure, Millennium Pharmaceutical, Amylin Pharmaceuticals, and Elan Pharmaceuticals

Comments